Deals Of The Week Wonders: Who Will Buy Onyx?
Executive Summary
Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.
You may also be interested in...
Deals Of The Week: Tire-Kicking Season Continues Full-Swing
As Roche’s reported interest in buying rare-disease specialist Alexion faded, new suitors popped up for oncology specialist Onyx. Plus news on deals between Spectrum and Talon, Pfizer and Sequella, Medtronic and Amgen, and a new direction for Rexahn.
Xencor Licenses Out IP To Help Fund Internal Pipeline
The California biotech has licensed intellectual property to Merck to help finance its own development efforts around immune-modulating drugs.
Onyx Starts Acquisition Process; Price And Competition To Come Into Play
The fast-growing biotech is soliciting bids, after a rejected Amgen offer and additional third party interest. Wall Street is scrambling to determine how to value Onyx and who the bidders could be.